http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Park, Young Soo,Na, Young-Soon,Ryu, Min-Hee,Lee, Chae-Won,Park, Hye Jin,Lee, Ju-Kyung,Park, Sook Ryun,Ryoo, Baek-Yeol,Kang, Yoon-Koo American Society for Clinical Pathology 2015 American journal of clinical pathology Vol.143 No.6
<P><B>Objectives:</B></P><P>Fibroblast growth factor receptor 2 <I>(FGFR2)</I> amplification has been reported to be a target for treatment in gastric cancer. However, an optimal tissue source and method for evaluating <I>FGFR2</I> have yet to be established.</P><P><B>Methods:</B></P><P>Copy numbers were compared by quantitative polymerase chain reaction (qPCR) using frozen vs formalin-fixed, paraffin-embedded (FFPE) tissue and biopsy vs surgical specimens. We correlated the results of qPCR and immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) using stage IV gastric cancer biopsy specimens and validated the results in surgical specimens.</P><P><B>Results:</B></P><P>FFPE tissues were suitable for qPCR, and biopsy specimens were equivalent to or better than surgical specimens. qPCR and IHC results exhibited an excellent correlation with FISH at eight or more copies by qPCR in any kind of tissue, 5% or more by IHC in biopsy specimens, and 10% or more by IHC in surgical specimens. <I>FGFR2</I> amplification was 6.6% in stage IV gastric cancers, and 42% of these showed heterogeneous amplification and overexpression. IHC indicated a good correlation with FISH even in the heterogeneous cases.</P><P><B>Conclusions:</B></P><P>FFPE biopsy tissues are an adequate source for <I>FGFR2</I> evaluation in gastric carcinomas, and a qPCR-based copy number assay can be used for screening. IHC is also a valid and practical method for evaluating <I>FGFR2</I>, considering frequent heterogeneity.</P>
Ryun Kyong Ha,Sung Chan Park,Boram Park,Sung Sil Park,Dae Kyung Sohn,Hee Jin Chang,Jae Hwan Oh 대한외과학회 2021 Annals of Surgical Treatment and Research(ASRT) Vol.101 No.1
Purpose: The effect of transanal total mesorectal excision (TaTME) on patients’ quality of life and functional outcomes is not fully understood. This study aimed to compare the quality of life and bowel, anorectal, and urogenital functions after laparoscopic and TaTME. Methods: Laparoscopic or TaTME was performed for 202 propensity score-matched patient pairs with rectal cancer between January 2014 and December 2017 at the National Cancer Center, Korea. The outcomes for all patients were assessed using anorectal manometry, the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and Colorectal Cancer-Specific Quality of Life Questionnaire (QLQ-CR38), low anterior resection syndrome (LARS) score, Fecal Incontinence Severity Index, and International Prostate Symptom Score (IPSS). This retrospective comparative study included patients who completed anorectal manometry and the questionnaires before treatment and at 1 year after surgery. Results: The EORTC QLQ-C30 and QLQ-CR38 showed comparable outcomes regarding the quality of life in both groups. More patients experienced major LARS in the transanal group at 1 year postoperatively (31.0% vs. 6.8% in the laparoscopic group, P = 0.004). Multivariable analysis revealed no significant difference in the LARS score between the groups at 1 year postoperatively (odds ratio, 2.30; 95% confidence interval, 0.79–6.72; P = 0.127). Significant differences in the IPSS were not noted between the groups. Conclusion: The quality of life and functional outcomes were comparable between the laparoscopic and transanal approaches; however, our findings suggest a higher rate of LARS after TaTME.